Abstract
HIV-infected individuals have excess rates of invasive pneumococcal disease. We investigated risk factors for nasopharyngeal pneumococcal colonization at baseline and after 9 months in 96 HIV patients immunized twice with 7- valent pneumococcal conjugate vaccine ±1mg CPG 7909.
In total, 22 patients (23%) were colonized, 11 at baseline only, four at both baseline and 9 months, and seven at 9 months only. Compared to non-colonized patients, more colonized patients were smokers, had lower CD4+ nadir and had an AIDS-diagnosis. Immunization, antiretroviral treatment and the CPG adjuvant had no impact on colonization. These results suggest preventive strategies in addition to pneumococcal immunization.
Keywords: HIV, Nasopharyngeal colonization, Pneumococcal vaccination, Risk factors, Smoking, S. Pneumoniae.
Current HIV Research
Title:Risk Factors for Pneumococcal Nasopharyngeal Colonization Before and After Pneumococcal Conjugate Vaccination in Persons with HIV: Brief Report
Volume: 10 Issue: 3
Author(s): Kristina Obrink-Hansen, Ole S. Søgaard, Zitta B. Harboe and Henrik C. Schonheyder
Affiliation:
Keywords: HIV, Nasopharyngeal colonization, Pneumococcal vaccination, Risk factors, Smoking, S. Pneumoniae.
Abstract: HIV-infected individuals have excess rates of invasive pneumococcal disease. We investigated risk factors for nasopharyngeal pneumococcal colonization at baseline and after 9 months in 96 HIV patients immunized twice with 7- valent pneumococcal conjugate vaccine ±1mg CPG 7909.
In total, 22 patients (23%) were colonized, 11 at baseline only, four at both baseline and 9 months, and seven at 9 months only. Compared to non-colonized patients, more colonized patients were smokers, had lower CD4+ nadir and had an AIDS-diagnosis. Immunization, antiretroviral treatment and the CPG adjuvant had no impact on colonization. These results suggest preventive strategies in addition to pneumococcal immunization.
Export Options
About this article
Cite this article as:
Obrink-Hansen Kristina, S. Søgaard Ole, B. Harboe Zitta and C. Schonheyder Henrik, Risk Factors for Pneumococcal Nasopharyngeal Colonization Before and After Pneumococcal Conjugate Vaccination in Persons with HIV: Brief Report, Current HIV Research 2012; 10 (3) . https://dx.doi.org/10.2174/157016212800618101
DOI https://dx.doi.org/10.2174/157016212800618101 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
What Characterizes Endothelial Dysfunction in Preeclampsia? -The Action of NO and the Production of Prostacyclin is Reduced, While EDHF is Preserved in Omental Resistance Arteries in Preeclamptic Women
Current Women`s Health Reviews Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication
Current Medicinal Chemistry Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry First and Second Generations of COX-2 Selective Inhibitors
Mini-Reviews in Medicinal Chemistry Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Formulation and in-vitro Evaluation of a Bilayer Matrix Tablet Containing Aceclofenac as Sustained Release and Paracetamol as Immediate Release
Drug Delivery Letters Practical Considerations in the Development of Hemoglobin-Based Oxygen Therapeutics
Current Drug Discovery Technologies Prolactin Induces IL-2 Associated TRAIL Expression on Natural Killer Cells from Chronic Hepatitis C Patients <i>In vivo</i> and <i>In vitro</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Mechanisms for Antiplatelet Action of Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [ Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer:Partners in Crime Guest Editor: Silvio Danese ]
Current Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design